The Russell 2000 is known as the world’s “biggest small index”. It offers investors the chance to invest in the heart of America. These small- and mid-cap stocks are diverse and offer more domestic focus than the multinational giants at the top of the S&P 500. In addition to providing important portfolio diversification, smaller companies typically outperform in the long run, owing to their greater scope for long-term growth.
Excluding the “Magnificent Seven” from the S&P 500’s return in 2023, it reveals that the remaining 493 stocks actually lagged the Russell 2000. Small caps have recently traded on historically wider discounts to large caps. However, 37% of the Russell 2000 index is unprofitable, and small caps have an average leverage ratio of 4.3 times. Disparities between market averages and individual stocks require active management to identify the winners and losers. Our investment process focuses on three key attributes: quality businesses, quality management and attractive valuations. Here are three firms that meet these criteria.
US small cap safe bets
MSA Safety (NYSE: MSA) is the global leader in the development, manufacturing and supply of safety products that protect people and facilities. MSA’s core products include self-contained breathing apparatus and other protective gear for firefighters; gas and flame detection systems used in a variety of industrial settings; and industrial head protection and fall-prevention equipment. Given the mission-critical and non-discretionary nature of safety products, MSA tends to experience less cyclicality than other industrial companies, with regular replacement of safety equipment often mandated by law. The company makes a healthy profit and requires limited capital investment, driving strong and durable cash flows.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Encompass Health (NYSE: EHC) is the largest operator of patient rehabilitation facilities in the US. As rehabilitation services are needs-based, patient volumes tend to be non-cyclical, while also benefiting from demographic trends as the US population ages. The combination of steady revenue growth, attractive profit margins and strong cash flows is a testament to the quality of the business, and we think Encompass’s strong management team and attractive valuation make the stock a promising investment.
MACOM Technology Solutions (Nasdaq: MTSI) designs and manufactures semiconductor technologies for optical, wireless and satellite networks. Macom has diversified exposure to applications in the industrial, telecommunications and data-centre markets, with the company’s multi-decade record and more than 600 patents underpinning a strong competitive position.
US small caps powered by artificial intelligence
Macom generates very attractive profit margins and strong cash flows, and is run by a management team with a history of creating value for shareholders. Recently, shares have benefited from the group’s exposure to optical components for artificial intelligence (AI) applications with data centres, which has driven a strong rally in shares. While we’ve taken some profits on recent strength, Macom remains a high-conviction position for the long term.
The US economy remains strong, with falling inflation and rising real wages offsetting dwindling savings and tighter credit conditions. We think moderate consumption growth should carry the US economy to a soft landing. We remain positive about small caps thanks to compelling valuations and strong fundamentals. Robust earnings growth, combined with low valuations, could drive small caps to regain the momentum of 2000-2011, when they outperformed. Investors remain underexposed to small caps. However, as their fundamental merits are rediscovered, we anticipate a return to the sector.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
-
Pierre-Édouard Stérin wants to make France great againConservative billionaire Pierre-Édouard Stérin is seeking to lead a political and spiritual renaissance across the Channel. The planning looks meticulous
-
Investors have overlooked emerging markets' top innovatorsOpinion Carlos Hardenberg, portfolio manager, Mobius Investment Trust, highlights three emerging market stocks where he’d put his money
-
Pierre-Édouard Stérin wants to make France great again
Conservative billionaire Pierre-Édouard Stérin is seeking to lead a political and spiritual renaissance across the Channel. The planning looks meticulous
-
Global investors have overlooked the top innovators in emerging markets
Opinion Carlos Hardenberg, portfolio manager, Mobius Investment Trust, highlights three emerging market stocks where he’d put his money
-
Pinewood Technologies: a drive for growthPinewood Technologies’ platform is one of the best in the business. Investors should buy in
-
'EV maker Faraday Future will crash'Faraday Future Intelligent Electric is failing dismally to live up to its name, says Matthew Partridge
-
Investors should cheer the coming nuclear summerThe US and UK have agreed a groundbreaking deal on nuclear power, and the sector is seeing a surge in interest from around the world. Here's how you can profit
-
8 of the best houses for sale with folliesThe best houses for sale with follies in the grounds – from a five-storey Victorian Gothic tower in Tonbridge, Kent, to a former mill in Oxfordshire with gardens that include a folly on an island in a lake
-
A tale of two Reits – why performance matters for valuationAEW UK and Regional are two Reits that are valued very differently, despite a shared focus on properties outside London
-
Healthcare stocks look cheap, but tread carefullyShares in healthcare companies could get a shot in the arm if uncertainty over policy in the US wanes, but are they worth the risk?
